Medtronic Secures FDA Clearance to Expand MiniMed 780G Insulin and CGM Compatibility

Medtronic has received 510(k) clearance from the US Food and Drug Administration (FDA) to expand use of its MiniMed 780G insulin pump with two ultra-rapid-acting insulins and an Abbott continuous glucose monitor (CGM). Issued in January, the clearance adds Novo Nordisk’s Fiasp and Eli Lilly’s Lyumjev to the list of insulins compatible with the automated insulin delivery system.

The FDA has also cleared the 780G system for use with Abbott’s Instinct CGM in people with Type 2 diabetes, enabling broader integration of Medtronic’s SmartGuard algorithm as an interoperable automated glycaemic controller. Sanofi’s Merilog, previously referenced in filings, is not included on the expanded label.

Medtronic said use of Fiasp and Lyumjev may reduce the impact of missed or delayed mealtime dosing due to their faster onset of action. Medicare and Medicare Advantage beneficiaries can now access the 780G-Instinct combination. The update comes as MiniMed, Medtronic’s planned diabetes spinout, prepares for its IPO.

09-02-2026